Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cancer Immunotherapy Market, By Product
7.1. Cancer Immunotherapy Market, By Product, 2021-2028
7.1.1. Monoclonal Antibodies
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Immunomodulators
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Oncolytic Viral Therapies and Cancer Vaccines
7.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Cancer Immunotherapy Market, By Cancer Type
8.1. Cancer Immunotherapy Market, By Cancer Type, 2021-2028
8.1.1. Lung Cancer
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Melanoma
8.1.4.1. Market Revenue and Forecast (2016-2028)
8.1.5. Prostate Cancer
8.1.5.1. Market Revenue and Forecast (2016-2028)
8.1.6. Head and Neck Cancer
8.1.6.1. Market Revenue and Forecast (2016-2028)
8.1.7. Ovarian Cancer
8.1.7.1. Market Revenue and Forecast (2016-2028)
8.1.8. Pancreatic Cancer
8.1.8.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
Chapter 10. Company Profiles
10.1. Amgen Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. AstraZeneca
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. F. Hoffman La Roche
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Bayer AG
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Bristol-Myers Squibb
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Eli Lilly and Co.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Merck and Co.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Novartis
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Pfizer
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms